Oragenics to host Neurotrauma Medicine webinar; will present ONP-002 mTBI update

ORAGENICS INC

Webinar scheduled for May 20, 2024, at 12:00 PM ET.
Lead drug candidate ONP-002, a neurosteroid for mild TBI, to be discussed.
Company to review preclinical/Phase I data and provide details on upcoming Phase II trial in acute/emergency settings.
No financial results or regulatory milestones announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.